You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCaptopril
Accession NumberDB01197  (APRD00164)
TypeSmall Molecule
GroupsApproved
Description

Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment of hypertension.

Structure
Thumb
Synonyms
(2S)-1-[(2S)-2-Methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
Acepress
Apopril
Capoten
Captolane
Captoprilum
Captopryl
Captoril
Cesplon
CP
D-2-Methyl-3-mercaptopropanoyl-L-proline
D-3-Mercapto-2-methylpropanoyl-L-proline
Dilabar
Garranil
Hypertil
L-Captopril
Lopirin
Tenosbon
Tensobon
Tensoprel
External Identifiers Not Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bci Captopril Tabletstablet50 mgoralBaker Cummins IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Bci Captopril Tabletstablet25 mgoralBaker Cummins IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Bci Captopril Tabletstablet100 mgoralBaker Cummins IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Bci Captopril Tabletstablet12.5 mgoralBaker Cummins IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Capoten Tab 100mgtablet100 mgoralBristol Myers Squibb Canada1981-12-312008-02-05Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Capoten Tab 12.5mgtablet12.5 mgoralBristol Myers Squibb Canada1990-12-312009-06-29Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Capoten Tab 25mgtablet25 mgoralBristol Myers Squibb Canada1981-12-312011-11-01Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Capoten Tab 50mgtablet50 mgoralBristol Myers Squibb Canada1981-12-312010-12-16Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Captopriltablet25 mgoralPharmel Inc1998-09-03Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Captopriltablet100 mgoralSorres Pharma Inc2000-10-262014-06-20Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Captopriltablet12.5 mgoralSorres Pharma Inc2000-10-262014-06-20Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Captopriltablet100 mgoralPharmel Inc1998-09-03Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Captopriltablet50 mgoralSorres Pharma Inc2000-10-262014-06-20Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Captopriltablet12.5 mgoralPharmel Inc1998-09-03Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Captopriltablet50 mgoralPharmel Inc1998-09-03Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Captopriltablet25 mgoralSorres Pharma Inc2000-10-262014-06-20Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Captopril Tabletstablet100 mgoralIvax Pharmaceuticals IncorporatedNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Captopril Tabletstablet50 mgoralIvax Pharmaceuticals IncorporatedNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Captopril Tabletstablet25 mgoralIvax Pharmaceuticals IncorporatedNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Captopril Tabletstablet12.5 mgoralIvax Pharmaceuticals IncorporatedNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Captopril-100 Tab 100mgtablet100 mgoralPro Doc Limitee1991-12-312000-07-31Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Captopril-12.5 Tab 12.5mgtablet12.5 mgoralPro Doc Limitee1991-12-312009-07-23Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Captopril-25 Tab 25mgtablet25 mgoralPro Doc Limitee1991-12-312012-07-23Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Captopril-50 Tab 50mgtablet50 mgoralPro Doc Limitee1991-12-312009-07-23Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Captriltablet12.5 mgoralTechnilab Pharma Inc.1998-06-302004-08-03Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Captriltablet100 mgoralTechnilab Pharma Inc.1998-06-302004-08-03Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Captriltablet50 mgoralTechnilab Pharma Inc.1998-06-302004-08-03Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Captriltablet25 mgoralTechnilab Pharma Inc.1998-06-302004-08-03Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Dom-captopriltablet50 mgoralDominion Pharmacal1998-09-17Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Dom-captopriltablet25 mgoralDominion Pharmacal1998-09-17Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Dom-captopriltablet12.5 mgoralDominion Pharmacal1998-09-17Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Dom-captopriltablet100 mgoralDominion Pharmacal1998-09-17Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ftp-captopriltablet50 mgoralFtp Pharmacal Inc.1998-10-092004-08-03Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ftp-captopriltablet25 mgoralFtp Pharmacal Inc.1998-10-092004-08-03Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ftp-captopriltablet12.5 mgoralFtp Pharmacal Inc.1998-10-092004-08-03Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Med Captopril - Tab 12.5mgtablet12.5 mgoralMedican Pharma Incorporated1996-07-302011-03-29Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Med Captopril - Tab 100mgtablet100 mgoralMedican Pharma Incorporated1996-07-092011-03-29Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Med Captopril - Tab 25mgtablet25 mgoralMedican Pharma Incorporated1996-08-222011-03-29Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Med Captopril - Tab 50mgtablet50 mgoralMedican Pharma Incorporated1996-07-302011-03-29Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Mylan-captopriltablet12.5 mgoralMylan Pharmaceuticals Ulc1995-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Mylan-captopriltablet25 mgoralMylan Pharmaceuticals Ulc1995-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Mylan-captopriltablet100 mgoralMylan Pharmaceuticals Ulc1995-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Mylan-captopriltablet50 mgoralMylan Pharmaceuticals Ulc1995-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Novo-captoriltablet6.25 mgoralNovopharm Limited1998-06-022005-08-10Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nu-capto Tab 100mgtablet100 mgoralNu Pharm Inc1991-12-312012-09-04Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nu-capto Tab 12.5mgtablet12.5 mgoralNu Pharm Inc1991-12-312012-09-04Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nu-capto Tab 25mgtablet25 mgoralNu Pharm Inc1991-12-312012-09-04Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nu-capto Tab 50mgtablet50 mgoralNu Pharm Inc1991-12-312012-09-04Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Orb-captopriltablet50 mgoralOrbus Pharma IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Orb-captopriltablet25 mgoralOrbus Pharma IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Penta-captopril Tabletstablet50 mgoralPentapharm Ltd.Not applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Penta-captopril Tabletstablet25 mgoralPentapharm Ltd.Not applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Penta-captopril Tabletstablet12.5 mgoralPentapharm Ltd.Not applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Penta-captopril Tabletstablet100 mgoralPentapharm Ltd.Not applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PMS-captopril - Tab 12.5mgtablet12.5 mgoralPharmascience Inc1998-06-17Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PMS-captopril - Tab 25mgtablet25 mgoralPharmascience Inc1998-06-17Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PMS-captopril - Tab 50mgtablet50 mgoralPharmascience Inc1998-06-17Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PMS-captopril - Tab 100mgtablet100 mgoralPharmascience Inc1998-06-17Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ratio-captopril Tab 100mgtablet100 mgoralRatiopharm Inc Division Of Teva Canada Limited1990-12-312006-08-04Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ratio-captopril Tab 12.5mgtablet12.5 mgoralRatiopharm Inc Division Of Teva Canada Limited1990-12-312006-08-04Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ratio-captopril Tab 25mgtablet25 mgoralRatiopharm Inc Division Of Teva Canada Limited1990-12-312006-08-04Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ratio-captopril Tab 50mgtablet50 mgoralRatiopharm Inc Division Of Teva Canada Limited1990-12-312006-08-04Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Teva-captopriltablet12.5 mgoralTeva Canada Limited1991-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Teva-captopriltablet100 mgoralTeva Canada Limited1991-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Teva-captopriltablet50 mgoralTeva Canada Limited1991-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Teva-captopriltablet25 mgoralTeva Canada Limited1991-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tria-captopril 100mg Tablettablet100 mgoralLaboratoires Trianon IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tria-captopril 12.5mg Tablettablet12.5 mgoralLaboratoires Trianon IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tria-captopril 25mg Tablettablet25 mgoralLaboratoires Trianon IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tria-captopril 50mg Tablettablet50 mgoralLaboratoires Trianon IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-capto Tab 100mgtablet100 mgoralApotex Inc1990-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-capto Tab 12.5mgtablet12.5 mgoralApotex Inc1990-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-capto Tab 25mgtablet25 mgoralApotex Inc1990-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-capto Tab 50mgtablet50 mgoralApotex Inc1990-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-capto Tab 6.25mgtablet6.25 mgoralApotex Inc1992-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Captopriltablet25 mg/1oralLegacy Pharmaceutical Packaging2009-09-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet12.5 mg/1oralWest Ward Pharmaceuticals Corp1996-02-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet50 mg/1oralPhysicians Total Care, Inc.1996-08-05Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet25 mg/1oralRebel Distributors Corp1997-03-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet50 mg/1oralApotex Corp.2005-12-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet12.5 mg/1oralWockhardt Limited1997-03-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet25 mg/1oralUnit Dose Services1996-02-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet100 mg/1oralbryant ranch prepack1996-02-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet12.5 mg/1oralGLENVIEW PHARMA INC.1997-03-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet100 mg/1oralMylan Pharmaceuticals Inc.1996-02-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet25 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet15 mg/1oralRed Pharm Drug Inc.1996-02-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet50 mg/1oralAidarex Pharmaceuticals LLC1997-03-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet100 mg/1oralGolden State Medical Supply, Inc.1996-02-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet12.5 mg/1oralUnit Dose Services1997-03-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet25 mg/1oralbryant ranch prepack1996-02-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet25 mg/1oralPreferred Pharmaceuticals, Inc.2012-03-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet50 mg/1oralMylan Pharmaceuticals Inc.1996-02-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet25 mg/1oralPd Rx Pharmaceuticals, Inc.1996-02-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet100 mg/1oralWockhardt USA LLC.1997-03-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet50 mg/1oralRebel Distributors Corp1996-02-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet50 mg/1oralGolden State Medical Supply, Inc.1996-02-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet100 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet25 mg/1oralREMEDYREPACK INC.2014-09-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet50 mg/1oralPreferred Pharmaceuticals, Inc.1996-02-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet25 mg/1oralMylan Pharmaceuticals Inc.1996-02-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet12.5 mg/1oralCardinal Health2011-04-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet50 mg/1oralUnit Dose Services1996-02-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet50 mg/1oralWockhardt USA LLC.1997-03-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet25 mg/1oralRebel Distributors Corp1996-02-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet25 mg/1oralGolden State Medical Supply, Inc.1996-02-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet50 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet25 mg/1oralSt Marys Medical Park Pharmacy2014-04-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet25 mg/1oralPreferred Pharmaceuticals, Inc.2012-12-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet12.5 mg/1oralMylan Pharmaceuticals Inc.1996-02-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet25 mg/1oralCardinal Health2011-04-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet30 mg/1oralREMEDYREPACK INC.2013-02-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet50 mg/1oralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet12.5 mg/1oralGolden State Medical Supply, Inc.1996-02-132017-03-30Us 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet12.5 mg/1oralAidarex Pharmaceuticals LLC1997-03-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet25 mg/1oralWockhardt USA LLC.1997-03-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet50 mg/1oralPreferred Pharmaceuticals, Inc.2012-12-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet100 mg/1oralWest Ward Pharmaceuticals Corp1996-02-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet25 mg/1oralCardinal Health2004-02-16Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet50 mg/1oralREMEDYREPACK INC.2011-06-16Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet50 mg/1oralSt Marys Medical Park Pharmacy2014-01-16Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet50 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1997-03-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet100 mg/1oralWockhardt Limited1997-03-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet25 mg/1oralREMEDYREPACK INC.2014-01-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet12.5 mg/1oralWockhardt USA LLC.1997-03-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet100 mg/1oralLegacy Pharmaceutical Packaging2009-09-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet50 mg/1oralWest Ward Pharmaceuticals Corp1996-02-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet50 mg/1oralCardinal Health2004-02-16Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet12.5 mg/1oralPd Rx Pharmaceuticals, Inc.2011-05-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet12.5 mg/1oralSt Marys Medical Park Pharmacy2014-04-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet50 mg/1oralGLENVIEW PHARMA INC.1997-03-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet25 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1997-03-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet50 mg/1oralWockhardt Limited1997-03-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet25 mg/1oralMylan Institutional Inc.1996-02-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet12.5 mg/1oralbryant ranch prepack1996-02-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet25 mg/1oralApotex Corp.2005-12-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet25 mg/1oralPhysicians Total Care, Inc.1996-04-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet12.5 mg/1oralLegacy Pharmaceutical Packaging2009-09-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet25 mg/1oralAidarex Pharmaceuticals LLC1997-03-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet50 mg/1oralLegacy Pharmaceutical Packaging2009-09-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet25 mg/1oralWest Ward Pharmaceuticals Corp1996-02-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet12.5 mg/1oralCardinal Health2004-02-16Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet50 mg/1oralRebel Distributors Corp1997-03-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet100 mg/1oralApotex Corp.2005-12-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet25 mg/1oralWockhardt Limited1997-03-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet12.5 mg/1oralMylan Institutional Inc.1996-02-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet50 mg/1oralbryant ranch prepack2009-09-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet25 mg/1oralGLENVIEW PHARMA INC.1997-03-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet12.5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1997-03-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet12.5 mg/1oralApotex Corp.2005-12-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet50 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet50 mg/1oralRed Pharm Drug Inc.1996-02-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Captopriltablet100 mg/1oralAidarex Pharmaceuticals LLC1997-03-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International Brands
NameCompany
AcepressBernofarm (Indonesia), BMS (Italy)
AceprilBMS (United Kingdom)
AlopresinNot Available
ApoprilNot Available
CapotenBristol-Myers Squibb, Par
CaptolaneSanofi-Aventis (France)
CaptorilNovopharm (Canada)
CesplonEsteve (Spain)
DilabarQualigen (Spain)
GarranilAristegui (Spain)
HipertilNormal (Portugal)
HypertilNormal (Portugal)
LopirinBMS (Germany,Switzerland)
LoprilOrion (Finland), BMS (France)
TenosbonNot Available
TensoprelRubio (Spain)
Brand mixtures
NameLabellerIngredients
Captopril and HydrochlorothiazideMylan Phamaceuticals Inc.
SaltsNot Available
Categories
CAS number62571-86-2
WeightAverage: 217.285
Monoisotopic: 217.077264041
Chemical FormulaC9H15NO3S
InChI KeyInChIKey=FAKRSMQSSFJEIM-RQJHMYQMSA-N
InChI
InChI=1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1
IUPAC Name
(2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
SMILES
C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-acyl-alpha amino acids. These are compounds containing an alpha amino acid which bears an acyl group at its terminal nitrogen atom.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentN-acyl-alpha amino acids
Alternative Parents
Substituents
  • N-acyl-alpha-amino acid
  • Pyrrolidine carboxylic acid or derivatives
  • Pyrrolidine carboxylic acid
  • N-acylpyrrolidine
  • Tertiary carboxylic acid amide
  • Pyrrolidine
  • Tertiary amine
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Alkylthiol
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of essential or renovascular hypertension (usually administered with other drugs, particularly thiazide diuretics). May be used to treat congestive heart failure in combination with other drugs (e.g. cardiac glycosides, diuretics, β-adrenergic blockers). May improve survival in patients with left ventricular dysfunction following myocardial infarction. May be used to treat nephropathy, including diabetic nephropathy.
PharmacodynamicsCaptopril, an ACE inhibitor, antagonizes the effect of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure using a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may sustain its effects by causing increased vasodilation and decreased blood pressure.
Mechanism of actionThere are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Captopril, one of the few ACE inhibitors that is not a prodrug, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Captopril also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors. Captopril’s affinity for ACE is approximately 30,000 times greater than that of ATI.
Absorption60-75% in fasting individuals; food decreases absorption by 25-40% (some evidence indicates that this is not clinically significant)
Volume of distributionNot Available
Protein binding25-30% bound to plasma proteins, primarily albumin
Metabolism

Hepatic. Major metabolites are captopril-cysteine disulfide and the disulfide dimer of captopril. Metabolites may undergo reversible interconversion.

SubstrateEnzymesProduct
Captopril
Not Available
captopril-cysteine disulfideDetails
Route of eliminationNot Available
Half life2 hours
ClearanceNot Available
ToxicitySymptoms of overdose include emesis and decreased blood pressure. Side effects include dose-dependent rash (usually maculopapular), taste alterations, hypotension, gastric irritation, cough, and angioedema.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.97
Blood Brain Barrier+0.6467
Caco-2 permeable+0.8867
P-glycoprotein substrateNon-substrate0.6276
P-glycoprotein inhibitor INon-inhibitor0.8448
P-glycoprotein inhibitor IINon-inhibitor0.7415
Renal organic cation transporterNon-inhibitor0.8073
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.6293
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9102
CYP450 2D6 inhibitorNon-inhibitor0.9537
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9049
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8975
Ames testNon AMES toxic0.8164
CarcinogenicityNon-carcinogens0.9434
BiodegradationNot ready biodegradable0.6577
Rat acute toxicity1.7403 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9604
hERG inhibition (predictor II)Non-inhibitor0.9118
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral100 mg
Tabletoral12.5 mg
Tabletoral25 mg
Tabletoral50 mg
Tabletoral6.25 mg
Tabletoral100 mg/1
Tabletoral12.5 mg/1
Tabletoral15 mg/1
Tabletoral25 mg/1
Tabletoral30 mg/1
Tabletoral50 mg/1
Tabletoral
Prices
Unit descriptionCostUnit
Captopril powder22.03USD g
Capoten 100 mg tablet4.53USD tablet
Capoten 12.5 mg tablet1.8USD tablet
Captopril 100 mg tablet1.53USD tablet
Captopril 50 mg tablet1.14USD tablet
Capoten 25 mg tablet1.13USD tablet
Capoten 50 mg tablet1.13USD tablet
Apo-Capto 100 mg Tablet1.09USD tablet
Mylan-Captopril 100 mg Tablet1.09USD tablet
Novo-Captoril 100 mg Tablet1.09USD tablet
Nu-Capto 100 mg Tablet1.09USD tablet
Captopril 25 mg tablet0.67USD tablet
Captopril 12.5 mg tablet0.62USD tablet
Apo-Capto 50 mg Tablet0.59USD tablet
Mylan-Captopril 50 mg Tablet0.59USD tablet
Novo-Captoril 50 mg Tablet0.59USD tablet
Nu-Capto 50 mg Tablet0.59USD tablet
Apo-Capto 25 mg Tablet0.31USD tablet
Mylan-Captopril 25 mg Tablet0.31USD tablet
Novo-Captoril 25 mg Tablet0.31USD tablet
Nu-Capto 25 mg Tablet0.31USD tablet
Apo-Capto 12.5 mg Tablet0.22USD tablet
Mylan-Captopril 12.5 mg Tablet0.22USD tablet
Novo-Captoril 12.5 mg Tablet0.22USD tablet
Nu-Capto 12.5 mg Tablet0.22USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
United States52389241993-08-242010-08-24
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point103-104Ondetti, M.A. and Cushman, D.W.; U.S. Patent 4,046,889; September 6, 1977; assigned t o E.R. Squibb & Sons, Inc. Ondetti, M.A. and Cushman, D.W.; U.S. Patent 4,105,776; August 8,1978; assigned to E.R. Squibb & Sons, Inc. Ondetti, M.A. and Cushman, D.W.; U.S. Patent 4,154,840; May 15,1979; assigned to E.R. Squibb & Sons, Inc.
water solubilityFreely solubleNot Available
logP0.34RANADIVE,SA ET AL. (1992)
Predicted Properties
PropertyValueSource
Water Solubility4.52 mg/mLALOGPS
logP1.02ALOGPS
logP0.73ChemAxon
logS-1.7ALOGPS
pKa (Strongest Acidic)4.02ChemAxon
pKa (Strongest Basic)-1.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area57.61 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity54.63 m3·mol-1ChemAxon
Polarizability21.72 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Charles M. Zepp, “Methods for preparing captopril and its analogues.” U.S. Patent US5166361, issued July, 1981.

US5166361
General References
  1. Atkinson AB, Robertson JI: Captopril in the treatment of clinical hypertension and cardiac failure. Lancet. 1979 Oct 20;2(8147):836-9. Pubmed
  2. Patchett AA, Harris E, Tristram EW, Wyvratt MJ, Wu MT, Taub D, Peterson ER, Ikeler TJ, ten Broeke J, Payne LG, Ondeyka DL, Thorsett ED, Greenlee WJ, Lohr NS, Hoffsommer RD, Joshua H, Ruyle WV, Rothrock JW, Aster SD, Maycock AL, Robinson FM, Hirschmann R, Sweet CS, Ulm EH, Gross DM, Vassil TC, Stone CA: A new class of angiotensin-converting enzyme inhibitors. Nature. 1980 Nov 20;288(5788):280-3. Pubmed
  3. Smith CG, Vane JR: The discovery of captopril. FASEB J. 2003 May;17(8):788-9. Pubmed
External Links
ATC CodesC09AA01
AHFS Codes
  • 24:32.04
PDB Entries
FDA labelNot Available
MSDSDownload (37.6 KB)
Interactions
Drug Interactions
Drug
AbirateroneThe serum concentration of Captopril can be increased when it is combined with Abiraterone.
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Captopril.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Captopril.
AlfuzosinAlfuzosin may increase the hypotensive activities of Captopril.
AliskirenAliskiren may increase the hyperkalemic activities of Captopril.
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Captopril.
Aluminum hydroxideThe serum concentration of Captopril can be decreased when it is combined with Aluminum hydroxide.
AmifostineCaptopril may increase the hypotensive activities of Amifostine.
AprotininAprotinin may decrease the antihypertensive activities of Captopril.
ArdeparinArdeparin may increase the hyperkalemic activities of Captopril.
AzathioprineCaptopril may increase the myelosuppressive activities of Azathioprine.
BrimonidineBrimonidine may increase the antihypertensive activities of Captopril.
ButabarbitalButabarbital may increase the hypotensive activities of Captopril.
ButethalButethal may increase the hypotensive activities of Captopril.
Calcium carbonateThe serum concentration of Captopril can be decreased when it is combined with Calcium carbonate.
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Captopril.
CiprofloxacinCaptopril may increase the arrhythmogenic activities of Ciprofloxacin.
CobicistatThe serum concentration of Captopril can be increased when it is combined with Cobicistat.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Captopril.
DarunavirThe serum concentration of Captopril can be increased when it is combined with Darunavir.
DiazoxideDiazoxide may increase the hypotensive activities of Captopril.
DrospirenoneCaptopril may increase the hyperkalemic activities of Drospirenone.
DuloxetineCaptopril may increase the orthostatic hypotensive activities of Duloxetine.
EplerenoneEplerenone may increase the hyperkalemic activities of Captopril.
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Captopril.
FluoxetineThe metabolism of Captopril can be decreased when combined with Fluoxetine.
HeparinHeparin may increase the hyperkalemic activities of Captopril.
HeptabarbitalHeptabarbital may increase the hypotensive activities of Captopril.
HexobarbitalHexobarbital may increase the hypotensive activities of Captopril.
IcatibantIcatibant may decrease the antihypertensive activities of Captopril.
InfliximabThe risk or severity of adverse effects can be increased when Captopril is combined with Infliximab.
IronThe risk or severity of adverse effects can be increased when Captopril is combined with Iron.
Iron DextranThe risk or severity of adverse effects can be increased when Captopril is combined with Iron Dextran.
LanthanumThe serum concentration of Captopril can be decreased when it is combined with Lanthanum.
LevodopaCaptopril may increase the orthostatic hypotensive activities of Levodopa.
LithiumThe serum concentration of Lithium can be increased when it is combined with Captopril.
Magnesium hydroxideThe serum concentration of Captopril can be decreased when it is combined with Magnesium hydroxide.
Magnesium oxideThe serum concentration of Captopril can be decreased when it is combined with Magnesium oxide.
MethohexitalMethohexital may increase the hypotensive activities of Captopril.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Captopril.
MolsidomineMolsidomine may increase the hypotensive activities of Captopril.
MoxonidineMoxonidine may increase the hypotensive activities of Captopril.
NicorandilNicorandil may increase the hypotensive activities of Captopril.
ObinutuzumabCaptopril may increase the hypotensive activities of Obinutuzumab.
PanobinostatThe serum concentration of Captopril can be increased when it is combined with Panobinostat.
Peginterferon alfa-2bThe serum concentration of Captopril can be decreased when it is combined with Peginterferon alfa-2b.
PentobarbitalPentobarbital may increase the hypotensive activities of Captopril.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Captopril.
PhenelzinePhenelzine may increase the orthostatic hypotensive activities of Captopril.
PregabalinThe risk or severity of adverse effects can be increased when Captopril is combined with Pregabalin.
PrimidonePrimidone may increase the hypotensive activities of Captopril.
QuinineQuinine may increase the hypotensive activities of Captopril.
RisperidoneCaptopril may increase the hypotensive activities of Risperidone.
RitonavirThe metabolism of Captopril can be decreased when combined with Ritonavir.
RituximabCaptopril may increase the hypotensive activities of Rituximab.
SacubitrilThe risk or severity of adverse effects can be increased when Captopril is combined with Sacubitril.
Salicylate-sodiumSalicylate-sodium may decrease the antihypertensive activities of Captopril.
SecobarbitalSecobarbital may increase the hypotensive activities of Captopril.
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Captopril.
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Captopril.
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Captopril is combined with Sodium aurothiomalate.
Sodium bicarbonateThe serum concentration of Captopril can be decreased when it is combined with Sodium bicarbonate.
TadalafilTadalafil may increase the antihypertensive activities of Captopril.
TemsirolimusThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Captopril.
TiclopidineThe metabolism of Captopril can be decreased when combined with Ticlopidine.
TizanidineTizanidine may increase the hypotensive activities of Captopril.
TolvaptanTolvaptan may increase the hyperkalemic activities of Captopril.
TorasemideTorasemide may increase the hypotensive activities of Captopril.
TranylcypromineTranylcypromine may increase the orthostatic hypotensive activities of Captopril.
TreprostinilTreprostinil may increase the hypotensive activities of Captopril.
TriamtereneTriamterene may increase the hyperkalemic activities of Captopril.
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Captopril.
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Captopril.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Captopril.
VardenafilVardenafil may increase the antihypertensive activities of Captopril.
YohimbineYohimbine may decrease the antihypertensive activities of Captopril.
Food Interactions
  • Captopril decreases the excretion of potassium. Salt substitutes containing potassium increase the risk of hyperkalemia.
  • Food decreases absorption by 25 - 40%. Clinical significance is debatable.
  • Herbs that may attenuate the antihypertensive effect of captopril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
  • High salt intake may attenuate the antihypertensive effect of captopril.

Targets

1. Angiotensin-converting enzyme

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Angiotensin-converting enzyme P12821 Details

References:

  1. Andujar-Sanchez M, Jara-Perez V, Camara-Artigas A: Thermodynamic determination of the binding constants of angiotensin-converting enzyme inhibitors by a displacement method. FEBS Lett. 2007 Jul 24;581(18):3449-54. Epub 2007 Jun 27. Pubmed
  2. Dalkas GA, Marchand D, Galleyrand JC, Martinez J, Spyroulias GA, Cordopatis P, Cavelier F: Study of a lipophilic captopril analogue binding to angiotensin I converting enzyme. J Pept Sci. 2010 Feb;16(2):91-7. Pubmed
  3. Natesh R, Schwager SL, Evans HR, Sturrock ED, Acharya KR: Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme. Biochemistry. 2004 Jul 13;43(27):8718-24. Pubmed
  4. Piepho RW: Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm. 2000 Oct 1;57 Suppl 1:S3-7. Pubmed
  5. Song JC, White CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. Pubmed
  6. Tzakos AG, Naqvi N, Comporozos K, Pierattelli R, Theodorou V, Husain A, Gerothanassis IP: The molecular basis for the selection of captopril cis and trans conformations by angiotensin I converting enzyme. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5084-7. Epub 2006 Aug 2. Pubmed
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

2. 72 kDa type IV collagenase

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
72 kDa type IV collagenase P08253 Details

References:

  1. Brower GL, Levick SP, Janicki JS: Inhibition of matrix metalloproteinase activity by ACE inhibitors prevents left ventricular remodeling in a rat model of heart failure. Am J Physiol Heart Circ Physiol. 2007 Jun;292(6):H3057-64. Epub 2007 Feb 16. Pubmed
  2. Okada M, Kikuzuki R, Harada T, Hori Y, Yamawaki H, Hara Y: Captopril attenuates matrix metalloproteinase-2 and -9 in monocrotaline-induced right ventricular hypertrophy in rats. J Pharmacol Sci. 2008 Dec;108(4):487-94. Epub 2008 Dec 5. Pubmed
  3. Prontera C, Mariani B, Rossi C, Poggi A, Rotilio D: Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. Int J Cancer. 1999 May 31;81(5):761-6. Pubmed
  4. Reinhardt D, Sigusch HH, Hensse J, Tyagi SC, Korfer R, Figulla HR: Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart. 2002 Nov;88(5):525-30. Pubmed
  5. Williams RN, Parsons SL, Morris TM, Rowlands BJ, Watson SA: Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models. Eur J Surg Oncol. 2005 Nov;31(9):1042-50. Epub 2005 Jul 1. Pubmed
  6. Yamamoto D, Takai S, Hirahara I, Kusano E: Captopril directly inhibits matrix metalloproteinase-2 activity in continuous ambulatory peritoneal dialysis therapy. Clin Chim Acta. 2010 May 2;411(9-10):762-4. Epub 2010 Feb 22. Pubmed

3. Matrix metalloproteinase-9

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Matrix metalloproteinase-9 P14780 Details

References:

  1. Okada M, Kikuzuki R, Harada T, Hori Y, Yamawaki H, Hara Y: Captopril attenuates matrix metalloproteinase-2 and -9 in monocrotaline-induced right ventricular hypertrophy in rats. J Pharmacol Sci. 2008 Dec;108(4):487-94. Epub 2008 Dec 5. Pubmed
  2. Reinhardt D, Sigusch HH, Hensse J, Tyagi SC, Korfer R, Figulla HR: Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart. 2002 Nov;88(5):525-30. Pubmed
  3. Williams RN, Parsons SL, Morris TM, Rowlands BJ, Watson SA: Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models. Eur J Surg Oncol. 2005 Nov;31(9):1042-50. Epub 2005 Jul 1. Pubmed
  4. Yamamoto D, Takai S, Miyazaki M: Inhibitory profiles of captopril on matrix metalloproteinase-9 activity. Eur J Pharmacol. 2008 Jul 7;588(2-3):277-9. Epub 2008 May 22. Pubmed

4. Leukotriene A-4 hydrolase

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Leukotriene A-4 hydrolase P09960 Details

References:

  1. Thunnissen MM, Andersson B, Samuelsson B, Wong CH, Haeggstrom J: Crystal structures of leukotriene A4 hydrolase in complex with captopril and two competitive tight-binding inhibitors. FASEB J. 2002 Oct;16(12):1648-50. Epub 2002 Aug 7. Pubmed

Enzymes

1. Cytochrome P450 2D6

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2D6 P10635 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Carriers

1. Serum albumin

Kind: Protein

Organism: Human

Pharmacological action: no

Actions: other/unknown

Components

Name UniProt ID Details
Serum albumin P02768 Details

References:

  1. Keire DA, Mariappan SV, Peng J, Rabenstein DL: Nuclear magnetic resonance studies of the binding of captopril and penicillamine by serum albumin. Biochem Pharmacol. 1993 Sep 14;46(6):1059-69. Pubmed
  2. Lin SY, Wei YS, Li MJ, Wang SL: Effect of ethanol or/and captopril on the secondary structure of human serum albumin before and after protein binding. Eur J Pharm Biopharm. 2004 May;57(3):457-64. Pubmed
  3. Mariee AD, Al-Shabanah O: Protective ability and binding affinity of captopril towards serum albumin in an in vitro glycation model of diabetes mellitus. J Pharm Biomed Anal. 2006 May 3;41(2):571-5. Epub 2006 Feb 15. Pubmed
  4. Narazaki R, Harada K, Sugii A, Otagiri M: Kinetic analysis of the covalent binding of captopril to human serum albumin. J Pharm Sci. 1997 Feb;86(2):215-9. Pubmed

Transporters

1. Multidrug resistance protein 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Multidrug resistance protein 1 P08183 Details

References:

  1. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500. Pubmed

2. Solute carrier family 15 member 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Solute carrier family 15 member 1 P46059 Details

References:

  1. Watanabe K, Sawano T, Terada K, Endo T, Sakata M, Sato J: Studies on intestinal absorption of sulpiride (1): carrier-mediated uptake of sulpiride in the human intestinal cell line Caco-2. Biol Pharm Bull. 2002 Jul;25(7):885-90. Pubmed
  2. Temple CS, Boyd CA: Proton-coupled oligopeptide transport by rat renal cortical brush border membrane vesicles: a functional analysis using ACE inhibitors to determine the isoform of the transporter. Biochim Biophys Acta. 1998 Aug 14;1373(1):277-81. Pubmed

3. Solute carrier family 22 member 6

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Solute carrier family 22 member 6 Q4U2R8 Details

References:

  1. Kuze K, Graves P, Leahy A, Wilson P, Stuhlmann H, You G: Heterologous expression and functional characterization of a mouse renal organic anion transporter in mammalian cells. J Biol Chem. 1999 Jan 15;274(3):1519-24. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:13